JPMorgan Raises Edgewise Therapeutics Price Target to $45 on Pipeline Confidence
Published on 3/30/2026
AI Summary
Summarized by AI from the source belowJPMorgan increased the price target for Edgewise Therapeutics, Inc. (EWTX) from $34 to $45 while maintaining an Overweight rating. This reflects optimism regarding the EDG-7500 pipeline and the upcoming release of 12-week data in Q2 2026, which may impact the outlook for EDG-7500. Additionally, long-term results from a study on sevasemten showed that patients maintained stable functional abilities over 3.5 years. The company also plans to present data from the GRAND CANYON pivotal cohort in Q4 2026, potentially aiding in regulatory approval for sevasemten.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News
Earnings
Cerebras (CRBS) Stock Falls 14% Despite Q2 Revenue of $180 Million
Aug 12
Earnings
Treasury Wine (TSY) Reports 42% Drop in Annual Profit Due to Weakness
Aug 12
Earnings
ANZ Reports Slightly Higher Profit Amid Property Tax Changes
Aug 12
Earnings
Top US Refiners Boost Profits and Increase Investor Rewards
Aug 12